{
    "clinical_study": {
        "@rank": "40078", 
        "arm_group": [
            {
                "arm_group_label": "SDAI remission group", 
                "arm_group_type": "Active Comparator", 
                "description": "SDAI remission"
            }, 
            {
                "arm_group_label": "Minimal disease activity group", 
                "arm_group_type": "Active Comparator", 
                "description": "Minimal disease activity remission"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the effect of two tight-control treatment strategies, aiming at 1) 2011\n      American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) definition\n      of remission compare with 2) minimal disease activity (Disease Activity Index in 28 joints\n      [DAS28] <2.6), on arterial stiffness in early rheumatoid arthritis (RA) patients.\n\n      To compare the effect of two treatments on arterial stiffness in Early Rheumatoid Arthritis"
        }, 
        "brief_title": "Early RA Vascular Randomised Controlled Study", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Early Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "One hundred RA patients with active disease (DAS28 >/=3.2), duration of symptoms less than 2\n      years,  and are disease modifying anti-rheumatic drug naive will participate in this 1-year\n      prospective, hospital-based, open-label, randomized, controlled trial.\n\n      All participants will receive 1-year tight-control treatment. One hundred patients will be\n      randomly assigned to two arms. Treatment will be adjusted according to a standardized\n      protocol every 3-monthly aiming at remission defined by the 2011 ACR/EULAR definition (Group\n      1, n=50, simplified disease activity score [SDAI] \u22643.3) or minimal disease activity (Group\n      2, n=50, DAS28<2.6)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  fulfilled the 2010 ACR/EULAR classification criteria for RA\n\n          -  have symptoms onset of less than 2 years\n\n          -  have active disease (DAS28> 3.2)\n\n          -  are positive for rheumatoid factor or anti-cyclic citrullinated protein\n             antibodies\n\n        Exclusion Criteria:\n\n          -  have a history of overt cardiovascular diseases\n\n          -  are on aspirin, or HMG-CoA reductase inhibitors (statins) or\n             angiotensin-converting-enzyme inhibitor (ACEI)\n\n          -  have severe renal impairment defined as a glomerular filtration rate of less than 30\n             ml/min/1.73m2\n\n          -  have been previously treated with tumor necrosis factor alpha (TNFa) inhibitors or\n             other biological DMARDs\n\n          -  on glucocorticoids at a dose >10mg/day"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768923", 
            "org_study_id": "ERA-Alx-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "SDAI remission group", 
                "description": "SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score [SDAI] <3.3)", 
                "intervention_name": "SDAI remission", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Minimal disease activity group", 
                "description": "Minimal disease activity group aims at minimal disease activity (DAS28<2.6) (minimal disease activity group)", 
                "intervention_name": "Minimal disease activity remission", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Early Rheumatoid Arthritis", 
            "Arterial stiffness", 
            "SDAI remission group", 
            "Minimal disease activity remission group"
        ], 
        "lastchanged_date": "January 14, 2013", 
        "location": {
            "contact": {
                "last_name": "Lai Shan Tam, MD", 
                "phone": "00852-2632 3996"
            }, 
            "facility": {
                "address": {
                    "city": "Hong Kong", 
                    "country": "China"
                }, 
                "name": "Prince of Wales Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Treat-to-target Strategies Aiming at Remission Compared With Minimal Disease Activity on Arterial Stiffness in Early Rheumatoid Arthritis - a Randomised Controlled Study", 
        "overall_contact": {
            "email": "lstam@cuhk.edu.hk", 
            "last_name": "Lai Shan Tam, MD", 
            "phone": "00852-2632 3996"
        }, 
        "overall_official": {
            "affiliation": "Chinese University of Hong Kong", 
            "last_name": "Lai Shan Tam, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The change in Alx@75 over 1-year of treatment", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768923"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese University of Hong Kong", 
            "investigator_full_name": "Lai-Shan Tam", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The proportion of patients achieve clinical remission (SDAI</= 3.3 or DAS28<2.6) after 1-year treatment", 
                "measure": "The proportion of patients achieve clinical remission", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "According to EULAR definition, good response is DAS28 < 3.2 and a fall in score from baseline by > 1.2", 
                "measure": "The proportion of patients with a good response", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "ACR 20, 50, 70 responses defined as at least 20%, 50%, 70% improvement in joint swelling and joint tenderness counts, and three of five other variables (i.e. ESR or CRP, HAQ score, pain score and physicians' and patients' global assessments)", 
                "measure": "ACR 20, 50, 70 responses", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Chinese University of Hong Kong", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese University of Hong Kong", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}